MarketCap
Facebook
X
TelegramQuarterly report 2024-Q3
added 11-19-2024
Renalytix AI plc Operating Income 2011-2026 | RNLX
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Renalytix AI plc
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -29.6 M | -42.2 M | -53.2 M | -31.9 M | -10.3 M | -42.3 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -10.3 M | -53.2 M | -34.9 M |
Quarterly Operating Income Renalytix AI plc
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -4.09 M | - | -6.55 M | -8.64 M | -8.89 M | - | -10.9 M | -9.65 M | -11.7 M | - | -14.5 M | -13.8 M | - | - | -8.07 M | -8.61 M | - | - | - | - | - | - | - | - | - | -567 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -567 K | -14.5 M | -8.84 M |
Operating Income of other stocks in the Diagnostics research industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Akumin
AKU
|
-28.1 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Burning Rock Biotech Limited
BNR
|
-797 M | $ 16.65 | -12.64 % | $ 179 M |  China |
|
Centogene N.V.
CNTG
|
-46 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Castle Biosciences
CSTL
|
8.67 M | $ 24.69 | - | $ 686 M |  USA |
 |
Agilent Technologies
A
|
1.35 B | $ 114.87 | - | $ 34.9 B | USA |
 |
Accelerate Diagnostics
AXDX
|
-14 M | - | -61.36 % | $ 2.46 M | USA |
 |
Illumina
ILMN
|
-833 M | $ 126.92 | - | $ 20.2 B | USA |
 |
Aspira Women's Health
AWH
|
-7.91 M | - | -6.19 % | $ 10.5 M | USA |
 |
Lantheus Holdings
LNTH
|
311 M | $ 83.55 | - | $ 5.64 B | USA |
 |
Biocept
BIOC
|
-32 M | - | -13.05 % | $ 7.29 M | USA |
 |
Chembio Diagnostics
CEMI
|
-23.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
553 M | $ 27.12 | - | $ 20 B |  Niderland |
 |
Check-Cap Ltd.
CHEK
|
-25.9 M | - | - | $ 9.42 M |  Israel |
 |
Co-Diagnostics
CODX
|
-50.2 M | $ 1.63 | - | $ 2.17 M | USA |
 |
Personalis
PSNL
|
-68.3 M | $ 5.5 | - | $ 326 M | USA |
 |
CareDx, Inc
CDNA
|
-30.8 M | $ 21.91 | - | $ 1.17 B | USA |
 |
Senseonics Holdings
SENS
|
-68.3 M | $ 7.18 | - | $ 300 M | USA |
 |
DermTech
DMTK
|
-104 M | - | -11.32 % | $ 2.94 M | USA |
 |
Enzo Biochem
ENZ
|
-12.4 M | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
-206 M | - | - | $ 19.8 B | USA |
 |
Fulgent Genetics
FLGT
|
-73.9 M | $ 15.3 | - | $ 463 M | USA |
 |
Trinity Biotech plc
TRIB
|
6.62 M | $ 0.61 | - | $ 61.9 M |  Irlanda |
 |
Twist Bioscience Corporation
TWST
|
-136 M | $ 59.15 | - | $ 3.54 B | USA |
 |
Global Cord Blood Corporation
CO
|
609 M | - | - | $ 399 M | China |
 |
Genetron Holdings Limited
GTH
|
-518 M | - | 0.12 % | $ 80.1 M | China |
 |
Charles River Laboratories International
CRL
|
25.2 M | $ 166.79 | 0.05 % | $ 8.27 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-20.8 M | - | -20.0 % | $ 1.06 M | USA |
 |
Guardant Health
GH
|
-437 M | $ 83.09 | - | $ 10.4 B | USA |
 |
Heska Corporation
HSKA
|
-20.3 M | - | - | $ 1.31 B | USA |
 |
Interpace Biosciences
IDXG
|
4.08 M | $ 1.93 | - | $ 8.54 M | USA |
 |
Exagen
XGN
|
-14.1 M | $ 2.73 | -0.36 % | $ 58.9 M | USA |
 |
QIAGEN N.V.
QGEN
|
466 M | - | - | $ 10.6 B | Niderland |
 |
Medpace Holdings
MEDP
|
535 M | $ 409.65 | - | $ 11.8 B | USA |
 |
Biomerica
BMRA
|
-5.14 M | $ 2.18 | -0.46 % | $ 5.01 M | USA |
 |
Motus GI Holdings
MOTS
|
-11.9 M | - | -34.28 % | $ 263 K | Israel |
 |
ICON Public Limited Company
ICLR
|
1.1 B | $ 102.49 | - | $ 8.45 B | Irlanda |
 |
Laboratory Corporation of America Holdings
LH
|
1.38 B | $ 259.57 | - | $ 21.6 B | USA |
 |
NeoGenomics
NEO
|
-116 M | $ 9.02 | - | $ 1.16 B | USA |
 |
Celcuity
CELC
|
-172 M | $ 120.07 | - | $ 5.61 B | USA |
 |
Neogen Corporation
NEOG
|
-1.06 B | $ 9.34 | - | $ 2.03 B | USA |
 |
National Research Corporation
NRC
|
22.6 M | $ 16.84 | -1.58 % | $ 377 M | USA |
 |
Myriad Genetics
MYGN
|
-387 M | $ 4.84 | - | $ 448 M | USA |
 |
Natera
NTRA
|
-541 M | $ 200.17 | - | $ 19.7 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
1.56 B | $ 195.05 | - | $ 21.7 B | USA |
 |
Invitae Corporation
NVTA
|
-94.9 M | - | - | $ 21.2 M | USA |
 |
OpGen
OPGN
|
325 K | - | -16.95 % | $ 1.54 M | USA |